Skip to main content
. Author manuscript; available in PMC: 2022 Mar 12.
Published in final edited form as: ACS Infect Dis. 2021 Feb 15;7(3):535–543. doi: 10.1021/acsinfecdis.0c00160

Figure 1. Phenazine production.

Figure 1.

(A) Biosynthesis of pyocyanin in P. aeruginosa. Adapted from references 16-19. (B) Production of phenazines upon treatment with compound 1. The production of PCA and pyocyanin (PYO) in wild-type P. aeruginosa PA14 (WT PA) is inhibited by compound 1, while heterologous PCA production in the recombinant E. coli (EC) strains are not inhibited. WT P. aeruginosa PA14 and the phz-containing E. coli strains were grown in MOPS-LB in the presence of DMSO or 1 (100 μM). PCA and PYO levels in cell-free supernatants were quantified by HPLC. Error bars represent the standard deviation of the mean of 3 replicates across 1 day (EC) or 15 replicates across 5 days (PA). Statistical significance was determined by t tests comparing the DMSO and compound 1 treatments within each strain. ****, p < 0.0001. (C) Inhibitor 1 blocks 99% production of pyocyanin at 100 μM in WT P. aeruginosa PA14 by the UV/Vis assay. Activity data from reference 9.